What clinical trials are available for metastatic Colorectal Cancer

Clinical Trials for Metastatic Colorectal Cancer

I'd be happy to help you understand the landscape of clinical trials for metastatic colorectal cancer (mCRC). However, I want to be upfront: I don't have a comprehensive, current database of all active clinical trials in my knowledge base. For the most complete and up-to-date trial information, you'll want to check ClinicalTrials.gov directly, which is the official U.S. registry maintained by the National Institutes of Health.

That said, I can share what the medical guidelines tell us about the types of trials and treatment approaches being studied for mCRC, which will help you understand what to look for:

---

Key Treatment Areas with Active Research

1. Chemotherapy Combinations

According to NCCN Guidelines for Colon Cancer, several chemotherapy regimens are standard and being refined in trials:

• FOLFOX (fluorouracil + leucovorin + oxaliplatin)
• CAPEOX (capecitabine + oxaliplatin)
• FOLFIRI (fluorouracil + leucovorin + irinotecan)
• FOLFIRINOX (combination of all four drugs above)

These are often combined with bevacizumab (a drug that blocks blood vessel growth to tumors).

2. Targeted Therapy Based on Biomarkers

For RAS/BRAF wild-type tumors (meaning these genes are normal):

• Trials combining chemotherapy with cetuximab or panitumumab (drugs that target EGFR)
• The NCCN Guidelines mention the VOLFI trial, which showed that adding panitumumab to FOLFOXIRI improved conversion rates from unresectable to resectable disease (75% vs. 36.4%)

For BRAF V600E mutations:

• Encorafenib + cetuximab/panitumumab + chemotherapy combinations

For HER2-amplified tumors:

• Trials with trastuzumab (Herceptin) combined with other targeted agents like pertuzumab, lapatinib, or tucatinib

3. Immunotherapy Trials

For patients with dMMR/MSI-H (deficient mismatch repair/microsatellite instability-high) tumors:

• Checkpoint inhibitors like:
  • Nivolumab (Opdivo)
  • Pembrolizumab (Keytruda)
  • Dostarlimab (Jemperli)
  • Combinations like nivolumab + ipilimumab

The NCCN Guidelines cite the CheckMate 142 trial showing durable responses with nivolumab in mCRC patients with mismatch repair deficiency.

4. Later-Line Therapies

For patients who've progressed through earlier treatments:

• Fruquintinib (a VEGFR inhibitor) - The NCCN Guidelines reference the FRESCO and FRESCO-2 trials, showing survival benefits in heavily pre-treated patients
• Regorafenib (CORRECT trial data in guidelines)
• Trifluridine-tipiracil (TAS-102) with or without bevacizumab

5. Neoadjuvant Immunotherapy

For resectable metastatic disease with dMMR/MSI-H or POLE/POLD1 mutations, trials are exploring checkpoint inhibitors before surgery to shrink tumors.

---

How to Find Trials Relevant to YOUR Situation

When searching ClinicalTrials.gov, you'll want to filter by:

1. Condition: "Metastatic colorectal cancer" or "mCRC"
2. Status: "Recruiting" or "Active, not recruiting"
3. Your biomarker status (if known):
   • KRAS/NRAS/BRAF mutation status
   • MSI-H/dMMR status
   • HER2 amplification status
4. Treatment phase: Phase 2 or Phase 3 trials typically have more established safety data
5. Location: Trials near you

---

Questions to Ask Your Oncologist

Since clinical trial eligibility depends heavily on your specific situation, ask your care team:

1. "Based on my tumor's biomarkers (KRAS, BRAF, MSI status, HER2), what clinical trials might I be eligible for?"

2. "Are there any trials at our institution or nearby cancer centers that match my disease stage and molecular profile?"

3. "What are the potential benefits and risks of trial participation compared to standard treatment options?"

4. "If I enroll in a trial, what happens if the experimental treatment isn't working—can I switch to standard therapy?"

5. "Will the trial cover treatment costs, and what about travel or additional monitoring?"

---

Authoritative Resources

• ClinicalTrials.gov - Search directly for mCRC trials: https://clinicaltrials.gov
• NCCN Guidelines for Colon Cancer - Outlines standard and investigational approaches
• American Cancer Society - Offers trial matching services
• Cancer Commons - Helps patients find relevant trials based on their tumor profile

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.